Gadolinium Based Contrast Agents GBCAs in Magnetic Resonance Imaging:

(Soumya Bandi[1], Medical content writer and Dr. Pranjal Bordoloi[2], SVP Medical and Clinical Affairs Jodas Expoim Pvt. Ltd)

Abstract:

Magnetic resonance imaging (MRI) is a crucial technique for disease diagnosis and treatment, with gadolinium-based contrast agents (GBCAs) being useful and safe in some cases. Elemental free gadolinium (Gd) is toxic to humans and is formed by chelating it to organic ligands. GBCAs have had a major influence on neuro-radiologic applications like as perfusion, MR angiography, and steady-state parenchymal imaging since their inception 25 years ago. Knowing an agent's relaxivity, concentration, and chelate stability is important for radiologists since these properties impact patient safety and the effectiveness of diagnosis.[1] MRI has been identified as the in vivo diagnostic technique of the future generation because to its many benefits, including minimal toxicity, the best soft-tissue contrast among all currently available imaging modalities, excellent spatial resolution, and lack of ionising radiation. The article summarises the existing scope of Gadolinium contrast media in diagnostic imaging.

Introduction:

Contrast agents are pharmaceuticals that enhance diagnostic image information by altering tissue properties, influencing contrast mechanisms. Image contrast refers to the difference in brightness between an area of interest and surroundings, making it easier to differentiate between different tissue types.[2]

Underlying mechanism in MRI:

For the diagnosis of internal body irregularities such as infections, illnesses of the vasculature, inflammatory disorders, neurodegenerative disorders, and tumours, magnetic resonance imaging (MRI) is an essential diagnostic technique. In addition, contrast agents (CAs) function as image-guiding mechanisms and theranostic modalities.[3]

Protons in biological systems are aligned using powerful magnetic fields in MRI, which then uses the protons' longitudinal or transverse relaxations to create images. Water molecules need to be polarised in order to produce strong contrast, however contrast becomes dull in internal organs like the brain.[3]

MRI is a technique used to study the proton (1H) relaxation processes in water and soft tissues in biological systems. The 1H nucleus generates a weak magnetic dipole, which aligns with the external field in two quantized energy states. The energy difference between these states is determined by the spin's gyromagnetic ratio, Planck's constant equation, and external magnetic field.[4]

$$\Delta E = \gamma \hbar B_0$$

The energy required for a 1H nuclear spin transition at external fields is 10−25 J, similar to radio waves in the electromagnetic spectrum. The magnetic moment precession towards the perpendicular plane is resonantly generated when a resonant radio frequency transverse pulse is supplied to B0. When the radiofrequency disturbance is eliminated, dipoles attain thermodynamic equilibrium. Longitudinal T1 relaxation (spin-lattice interaction) and transverse T2 relaxation (random fluctuations in local field strength produced by neighbouring spins) characterise the relaxation behaviour of dipoles.[4]

Importance of GBCAs:

GBCAs are paramagnetic substances used to enhance the visibility of certain tissues and structures on MRI scans. To provide contrast in magnetic resonance imaging, elements other than gadolinium can be used. These compounds have been approved to study the liver using iron oxide nanoparticles and a manganese (II) complex; however, they have not proven marketable. Lanthanides, particularly Gadolinium (Gd3+), are used in complex contrast agents due to their higher magnetic moment than protons. Gadolinium, with seven unpaired electrons, has optimal electron spin relaxation and stable molecules. Although other lanthanides have higher magnetic moments, free Gd3+ ions are toxic, and chelation can reduce side effects.[9]

GBCAs shorten the T1 and T2 relaxation times of water molecules, resulting in brighter signals on T1-weighted images and darker signals on T2-weighted images. The mechanism of this process is complex and depends on factors like GBCA structure and water molecules' environment. Relaxation enhancement is the process by which GBCAs transfer energy to water molecules, causing them to flip their spins more quickly.

Three MRI contrast agents were approved for clinical use in the US since 1994, followed by six more from 1995 to 2017: gadopentetate dimeglumine, gadodiamide, Gadoteridol,

gadoterate meglumine, Dotarem®, gadobenate dimeglumine, and gadobutrol. These agents were approved by the FDA for clinical use.[2]

GBCAs in Medical Imaging:

GBCAs interact with the strong magnetic field used in MRI to produce higher signal intensity. They are administered intravenously and are distributed throughout the body. GBCAs are extracted by the kidneys, with most being eliminated within hours.[5]

GBCAs, created by chelating a toxic free gadolinium ion with a ligand, protect tissues from interactions with Gd3+ ions and facilitate rapid renal clearance, minimizing biotransformation and accumulation. Their pharmacokinetics are also controlled by the chelating process.[6] Non-ionic linear, ionic linear, and macrocyclic are the three unique stability classes into which GBCAs fall. There is a difference in stability between macrocyclic and linear chelates, and between ionic and non-ionic linear chelates.[7] GBCAs are classified into two groups: open-chain or linear molecules and macrocyclic compounds with the Gd3+ ion caged inside the ligand cavity. Ionic and non-ionic characteristics are present in these compounds.



Figure: 1[8]

Figure: An example of a T1 weighted picture that displays the action of gadoteridol, a T1 contrast agent, at 3 T in the brain of a patient suffering from glioblastoma. The tumour exhibits substantial and positive enhancement twenty minutes after the gadoteridol injection (picture on right), as compared to the T1 weighted image obtained before to injection (left).[8]

These extracellular agents are the most often utilised contrast agents in clinical practice since they are unable to pass the intact blood-brain barrier. The faster injection of Gd molecules, resulting in a sharper contrast bolus, may increase the susceptibility effect in the tissue of interest during image acquisition, thereby enhancing the contrast bolus.[1]

When administered at relatively low doses (0.1–0.3 mmol/kg) in individuals with normal renal function, all GBCAs approved for clinical use have been found to have a broad safety margin. With major adverse events occurring in only 0.03% of all doses, the cumulative safety record is excellent.[7]

Conclusion:

MRI uses strong magnetic fields to align protons in biological systems, and then uses their longitudinal or transverse relaxations to create pictures. Contrast agents are medications that modify tissue characteristics and impact contrast processes to enhance diagnostic image information. They have become an integral feature of modern magnetic resonance imaging. Contrast agents are frequently added to MRIs to increase sensitivity and/or specificity, despite the initial intention that this would allow for the rendering of conclusive diagnoses without the need for them. These agents serve as theranostic modalities as well as strategies for guiding images. GBCAs are paramagnetic materials that are applied to MRI images to improve the visibility of specific tissues and structures. Tumour growths and other diseases can be diagnosed more easily when particular soft tissue areas are highlighted by the contrast-enhanced MRI scan. Radiologists can recognise serious developments more easily because of this contrast. Arteries and veins appear as "flow voids" on the scan because the dye helps separate the lifeblood from flowing fluid.

References:

1. Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. *AJNR Am J Neuroradiol*. 2014;35(12):2215-2226. doi:10.3174/ajnr.A3917

2. Ibrahim MA, Hazhirkarzar B, Dublin AB. Gadolinium Magnetic Resonance Imaging. In: *StatPearls*. StatPearls Publishing; 2024. Accessed April 29, 2024. http://www.ncbi.nlm.nih.gov/books/NBK482487/

3. Lv J, Roy S, Xie M, Yang X, Guo B. Contrast Agents of Magnetic Resonance Imaging and Future Perspective. *Nanomater Basel Switz*. 2023;13(13):2003. doi:10.3390/nano13132003

4. Tu C, Osborne EA, Louie AY. Activatable T_1 and T_2 magnetic resonance imaging contrast agents. *Ann Biomed Eng*. 2011;39(4):1335-1348. doi:10.1007/s10439-011-0270-0

5. Costelloe CM, Amini B, Madewell JE. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. *Semin Ultrasound CT MR*. 2020;41(2):170-182. doi:10.1053/j.sult.2019.12.005

6. Ranga A, Agarwal Y, Garg KJ. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function. *Indian J Radiol Imaging*. 2017;27(2):141-147. doi:10.4103/0971-3026.209212

7. Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. *AJNR Am J Neuroradiol*. 2016;37(7):1192-1198. doi:10.3174/ajnr.A4615

8. Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. *Chem Rev*. 2019;119(2):957-1057. doi:10.1021/acs.chemrev.8b00363

9. Smeraldo A, Netti PA, Torino E. New Strategies in the Design of Paramagnetic CAs. *Contrast Media Mol Imaging*. 2020;2020:4327479. doi:10.1155/2020/4327479